Both moxifloxacin negative controls (gyrA S95T & A90S) were correctly predicted to not affect the binding of moxifloxacin to the DNA gyrase. Although hyper-susceptibility is expected for A90S, the magnitude of the confidence limits prevents us drawing any conclusions. No definite prediction could be made for any of the three mutations associated with moxifloxacin resistance since the confidence limits of all three mutations straddled the clinical threshold. Unlike the RNA polymerase, two of the mutations to the DNA gyrase involved charged residues (gyrB E501D & gyrA D94G) and not surprisingly these had the largest estimated errors.